Clinical Trial Update: TMC125-C216: A Phase III Study to Investigate the Efficacy, Tolerability and Safety of TMC125 as Part of an Antiretroviral Regimen, Including TMC114/Ritonavir and an Investigator-selected Optimized Background, in HIV-1 Infected Patients With Limited to no Treatment Options. [Phase 3]

View source ↗

Summary

Phase III study TMC125-C216 evaluates etravirine (TMC125) as part of an antiretroviral regimen including TMC114/ritonavir in HIV-1 infected patients with limite…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Intelence (etravirine) (etravirine)
• Norvir (ritonavir) (ritonavir)
• Prezista (darunavir) (darunavir)

Snippet

Sponsor: Tibotec Pharmaceuticals, Ireland | Conditions: HIV | Phase 3 | Status: COMPLETED